NCT04992468 - Dual Trigger for Elective Fertility Preservation | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions

Infertility

Interventions

DRUG

Ovulation triggering with GnRH-a+rhCG

recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)

DRUG

Ovulation triggering with GnRH-a

rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)

Trial Locations (1)

08028

Hospital Universitario Quiron Dexeus, Barcelona

All Listed Sponsors

lead

Fundación Santiago Dexeus Font

OTHER